The Half That Was Left Behind: How Cytokinetics Just Opened the Door for Non-Obstructive HCM

For years, the story of hypertrophic cardiomyopathy treatment has been told in two halves. The obstructive half got the drugs. The non-obstructive half got told to wait.

On May 5, 2026, Cytokinetics announced that the waiting is over. The company's pivotal Phase 3 ACACIA-HCM trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy met both of its dual primary endpoints, delivering statistically significant improvements in symptom burden and exercise capacity compared to placebo at 36 weeks. The stock surged 28 percent on the news. The more important number, however, is not the share price. It is the zero: the number of currently approved therapies for non-obstructive HCM before this trial read out.

What the Data Actually Show

ACACIA-HCM randomized 516 participants outside Japan on a 1:1 basis to aficamten or placebo. The dual primary endpoints were the change from baseline to Week 36 in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, a validated patient-reported measure of symptoms and quality of life, and peak oxygen uptake, or pVO2, the gold standard measure of maximal exercise capacity. Both endpoints were met with statistical significance. Aficamten produced a 3.0-point improvement in KCCQ-CSS over placebo (p=0.021) and a 0.67 mL/kg/min improvement in pVO2 (p=0.003). Key secondary endpoints, including improvements in New York Heart Association functional class, ventilatory efficiency, and NT-proBNP, a biomarker of cardiac stress, were all met with p-values below 0.001.

The safety picture requires honest accounting. Left ventricular ejection fraction fell below 50 percent in 10 percent of patients on aficamten compared to 1 percent on placebo, and two patients experienced serious adverse events of heart failure associated with that LVEF decline. These are not trivial findings. Aficamten works by reducing cardiac contractility, and that mechanism carries an inherent risk of overshooting into systolic dysfunction. The drug already carries a boxed warning for this risk in its approved obstructive HCM label, and the REMS program requiring echocardiographic monitoring before and during treatment exists precisely because of it. The ACACIA-HCM data do not change that risk profile, but they do confirm that it is manageable within a structured monitoring framework.

Why Non-Obstructive HCM Has Been So Hard to Treat

Hypertrophic cardiomyopathy is the most common monogenic inherited cardiovascular disorder, with more than 300,000 patients diagnosed in the United States and an estimated 400,000 to 800,000 additional patients who remain undiagnosed. Roughly half of those diagnosed have the obstructive form, in which thickened heart muscle physically blocks blood flow out of the left ventricle. The other half have non-obstructive HCM, in which the obstruction is absent but the underlying hypercontractility of the cardiac muscle still impairs the heart's ability to relax, fill, and pump efficiently.

That distinction has mattered enormously for drug development. The obstructive form has a measurable hemodynamic target: the left ventricular outflow tract gradient. Reducing that gradient is a clear, objective endpoint that regulators and clinicians can evaluate. The non-obstructive form lacks that convenient proxy. Patients still experience breathlessness, fatigue, chest pain, and reduced exercise tolerance, but the mechanism driving those symptoms is more diffuse and harder to quantify. That complexity has historically made non-obstructive HCM a less attractive development target, and it explains why the field has had approved therapies for oHCM since Bristol Myers Squibb's mavacamten received FDA approval in 2022, while nHCM patients have had nothing.

What Comes Next for Aficamten and the Field

Cytokinetics has indicated it will present the full ACACIA-HCM dataset at an upcoming medical congress and then engage with the FDA and other regulatory authorities about a path to approval in non-obstructive HCM. The company already has a supplemental NDA under FDA review for a separate indication, the MAPLE-HCM data in obstructive HCM, with a PDUFA date of November 14, 2026. The ACACIA-HCM data would form the basis of a separate regulatory submission, likely a further supplemental NDA, that could expand aficamten's label to cover the full HCM spectrum.

That breadth matters commercially and clinically. A drug approved for both obstructive and non-obstructive HCM would be the only therapy in the field with that scope. Mavacamten, the only other approved cardiac myosin inhibitor, has no Phase 3 data in non-obstructive HCM. Cytokinetics has now established a meaningful lead in the nHCM space that its competitor will need years to close, if it chooses to pursue it at all.

The broader implication of ACACIA-HCM extends beyond competitive positioning. The trial is the first to demonstrate statistically significant improvements in both exercise capacity and symptom burden in non-obstructive HCM patients in a randomized, placebo-controlled setting. That is a scientific statement about the disease itself: that the hypercontractility driving nHCM is a pharmacologically tractable target, and that reducing it with a cardiac myosin inhibitor produces measurable, meaningful benefit for patients who have had no approved options. For the roughly 150,000 to 400,000 Americans with non-obstructive HCM who have been managing their disease with off-label medications and lifestyle modifications, that statement is not an abstraction. It is the beginning of a different conversation with their cardiologist.